Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 3/20 | 1.00 |
| ▸ | FNTA | P49354 | 1/20 | 0.39 |
| ▸ | FNTB | P49356 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11834615 | 0.78 | MAT2A (0.64) | MAT2AFNTAFNTBOPRK1HPGD | |
| SCHEMBL30787877 | 0.76 | MAT2A (0.62) | MAT2AFNTAFNTBKDM4EHPGD | |
| SCHEMBL5794890 | 0.70 | MAT2A (0.53) | MAT2AFNTAFNTB | |
| SCHEMBL11846031 | 0.70 | MAT2A (0.53) | MAT2AFNTAFNTBOPRK1MAPK1 | |
| Hydrochloric Acid SCHEMBL11452275 | 0.67 | MAT2A (0.50) | MAT2AHTR6CYP1A2CYP2D6KDM4E | |
| Hydrochloric Acid SCHEMBL11452185 | 0.67 | MAT2A (0.50) | MAT2AHTR6CYP1A2CYP2D6KDM4E | |
| SCHEMBL10513759 | 0.66 | MAPT (0.51) | MAT2ACYP1A2CYP2D6KDM4EPDE10A | |
| SCHEMBL11825860 | 0.65 | MAT2A (0.48) | MAT2AFNTAFNTBOPRK1KDM4E | |
| SCHEMBL7327610 | 0.65 | OPRK1 (0.81) | MAT2AOPRK1KDM4EHPGD | |
| SCHEMBL11835478 | 0.65 | MAPT (0.59) | MAT2AHTR6CYP1A2CYP2D6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240075017-A1 | TREATMENT OF CORONAVIRUS INFECTIONS USING SAM CYCLE INHIBITORS | UNIV MUENCHEN TECH (DE) | 2024-03-07 | — | — | US | claimed |
| EP-4304573-A1 | TREATMENT OF CORONAVIRUS INFECTIONS USING SAM CYCLE INHIBITORS | Technische Universität München (DE) | 2024-01-17 | — | — | EP | claimed |
| CN-114672551-B | Application of MAT2A and MAT2B as drug targets for detecting or treating benign prostatic hyperplasia | 中国医科大学附属第一医院 | 2023-03-31 | — | — | CN | claimed |
| CN-114028572-B | Novel use of MAT2A inhibitor for treating asthma | 清华大学 | 2022-11-25 | — | — | CN | claimed |
| WO-2022189379-A1 | TREATMENT OF CORONAVIRUS INFECTIONS USING SAM CYCLE INHIBITORS | Technische Universität München (DE) | 2022-09-15 | — | — | WO | claimed |
| US-11376256-B2 | Method of treating a methionine-dependent cancer | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-07-05 | — | — | US | claimed |
| CN-114672551-A | Application of MAT2A and MAT2B as drug targets for detecting or treating benign prostatic hyperplasia | 中国医科大学附属第一医院 | 2022-06-28 | — | — | CN | claimed |
| US-20250364077-A1 | GENERALIZED PROBABILISTIC GENERATIVE MODELING METHOD FOR ANALYSIS OF TUMOR METHYLATED MOLECULES IN TARGET CAPTURE REGIONS | GUARDANT HEALTH, INC. | 2025-11-27 | — | — | US | disclosed |
| WO-2025245433-A1 | GENERALIZED PROBABILISTIC GENERATIVE MODELING METHOD FOR ANALYSIS OF TUMOR METHYLATED MOLECULES IN TARGET CAPTURE REGIONS | GUARDANT HEALTH, INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| WO-2025235602-A1 | PREDICTIVE, PROGNOSTIC SIGNATURES FOR IMMUNO-ONCOLOGY USING LIQUID BIOPSY | GUARDANT HEALTH, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| WO-2025217297-A1 | PRMT5 INHIBITORS FOR USE IN METHODS OF TREATING MTA-ACCUMULATING CANCER | TANGO THERAPEUTICS, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| EP-4608511-A1 | CRYSTALLINE FORMS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | Tango Therapeutics, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250250638-A1 | GENOMIC AND METHYLATION BIOMARKERS FOR PREDICTION OF COPY NUMBER LOSS / GENE DELETION | GUARDANT HEALTH, INC. | 2025-08-07 | — | — | US | disclosed |
| WO-2022174234-A2 | BIOMARKERS FOR CANCER TREATMENT | FOUNDATION MEDICINE, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| US-11376256-B2 | Method of treating a methionine-dependent cancer | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-07-05 | — | — | US | disclosed |
| US-11376256-B2 | Method of treating a methionine-dependent cancer | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-07-05 | — | — | US | disclosed |
| CN-114672551-A | Application of MAT2A and MAT2B as drug targets for detecting or treating benign prostatic hyperplasia | 中国医科大学附属第一医院 | 2022-06-28 | — | — | CN | disclosed |
| CN-114672551-A | Application of MAT2A and MAT2B as drug targets for detecting or treating benign prostatic hyperplasia | 中国医科大学附属第一医院 | 2022-06-28 | — | — | CN | disclosed |
| CN-114028572-A | Novel use of MAT2A inhibitor for treating asthma | 清华大学 | 2022-02-11 | — | — | CN | disclosed |
| WO-2021158792-A1 | METHODS OF TREATING AUTOIMMUNE OR INFLAMMATORY DISEASES OR DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11376256-B2 | Method of treating a methionine-dependent cancer | MGMT, BHMT2, MTR | MAT2A 8/4885FNTA 2887/4885FNTB 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.